Wolverine Trading
LGND icon

Wolverine Trading’s Ligand Pharmaceuticals LGND Stock Holding History

Wolverine Trading’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,974
Closed -$212K – 5218
2025
Q1 		$212K Buy
+1,974
New +$223K ﹤0.01% 3892
2022
Q1 		– Sell
-2,092
Closed -$204K – 5989
2021
Q4 		$204K Buy
+2,092
New +$193K ﹤0.01% 4684
2020
Q1 		– Sell
-8,312
Closed -$539K – 4962
2019
Q4 		$539K Sell
8,312
-12,280
-60% -$821K ﹤0.01% 3002
2019
Q3 		$1.27M Sell
20,592
-4,844
-19% -$304K ﹤0.01% 1776
2019
Q2 		$1.81M Sell
25,436
-28,899
-53% -$2.13M 0.01% 1580
2019
Q1 		$4.26M Buy
54,335
+29,936
+123% +$2.27M 0.01% 983
2018
Q4 		$2.07M Buy
+24,399
New +$2.6M 0.01% 1381

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Trading's LGND Position: Q2 2025 in Review

Wolverine Trading sold out of Ligand Pharmaceuticals (LGND) in Q2 2025, closing a stake of 1,974 shares — an estimated $212K sold.

Wolverine Trading first reported a position in LGND in Q4 2018 and held it in 7 quarters. The position peaked at $4.26M in Q1 2019. 271 funds tracked by Wall St. Rank hold LGND as of Q2 2025.

  • Wolverine Trading reported no remaining Ligand Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Wolverine Trading sold 1,974 Ligand Pharmaceuticals shares in Q2 2025, an estimated $212K.
  • Wolverine Trading first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 7 quarters.
  • Wolverine Trading's Ligand Pharmaceuticals position peaked at $4.26M in Q1 2019.
  • 271 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2025.

Based on Wolverine Trading's 13F filing for Q2 2025, filed 18 Aug 2025.